Eli Lilly agreed to acquire AtaiBeckley in a deal valued at up to $3.8 billion, aiming to expand its neuroscience portfolio with AtaiBeckley’s late-stage pipeline. Analysts cited Eli Lilly’s willingness to lean into psychedelics-era mental health R&D as a sign of a shifting regulatory and clinical landscape. The acquisition centers on BPL-003 (mebufotenin benzoate), a Phase III candidate for treatment-resistant depression (TRD) that uses an intranasal approach. The program has received FDA Breakthrough Therapy designation, and earlier Phase 2a results showed rapid and sustained MADRS score reductions in patients who remained on stable SSRI therapy. Lilly is set to pay $2.8 billion upfront, with the remainder tied to milestones, and the transaction is expected to close in the third quarter. The move underscores how investors and major pharma are reorganizing portfolios around TRD and next-generation antidepressant mechanisms.